(Q34451681)

English

Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

1 reference

ChEBI release 2020-05-28

1 reference

based on heuristic

inferred from title

Hepatitis C virus

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

object named as

Nina Weis

9

0 references

6

object named as

Stanislas Pol

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

1

object named as

Mark Sulkowski

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

3

object named as

Jan Gerstoft

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

author name string

Christophe Hezode

2

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

John M Vierling

4

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Josep Mallolas

5

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Marcelo Kugelmas

7

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Abel Murillo

8

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Ronald Nahass

10

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Oren Shibolet

11

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Lawrence Serfaty

12

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Marc Bourliere

13

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Edwin DeJesus

14

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Eli Zuckerman

15

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Frank Dutko

16

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Melissa Shaughnessy

17

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Peggy Hwang

18

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Anita Y M Howe

19

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Janice Wahl

20

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Michael Robertson

21

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Eliav Barr

22

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Barbara Haber

23

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

language of work or name

0 references

publication date

11 November 2014

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

385

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

9973

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

1087-1097

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961793-1

7 January 2021

based on heuristic

inferred from DOI database lookup

UNITAID can address HCV/HIV co-infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961793-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Global epidemiology and genotype distribution of the hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961793-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of HCV infection on cause-specific mortality after HIV seroconversion, before and after 1997.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961793-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961793-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Gaps in the achievement of effectiveness of HCV treatment in national VA practice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961793-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A global view of hepatitis C: physician knowledge, opinions, and perceived barriers to care

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961793-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961793-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961793-1

7 January 2021

based on heuristic

inferred from DOI database lookup

EASL recommendations on treatment of hepatitis C 2014.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961793-1

7 January 2021

based on heuristic

inferred from DOI database lookup

MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961793-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961793-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative analysis of two rates

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961793-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961793-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961793-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961793-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961793-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Peginterferon alfa-2a plus ribavirin for HIV-HCV genotype 1 coinfected patients: a randomized international trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961793-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961793-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961793-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961793-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961793-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961793-1

7 January 2021

based on heuristic

inferred from DOI database lookup

ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961793-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961793-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961793-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(14)61793-1

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

release_tft4fzuh5zhahlnsjbbyiervcm

1 reference

https://api.fatcat.wiki/v0/release/tft4fzuh5zhahlnsjbbyiervcm

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34451681&oldid=1945334865"